Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
Helix TCS (OTC: HLIX) CEO Zachary Venegas talks cannabis industry M&A in technology and security services. Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over […]
Article reported GP Solutions is a leader, and “growing rapidly” in the $3 billion market CORONA, Calif., Aug. 12, 2019 — GP Solutions (OTC: GWPD a leading developer of automated micro-farms, is pleased to announce it was named one […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
